Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

Vericel Co. (NASDAQ:VCEL) – Stock analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Vericel in a report released on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now forecasts that the biotechnology company will post earnings per share of $0.48 for the quarter, up from their previous estimate of $0.45. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel’s FY2029 earnings at $2.76 EPS.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $52.60 million during the quarter, compared to the consensus estimate of $53.86 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis.

Several other research firms also recently weighed in on VCEL. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Truist Financial decreased their price objective on shares of Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Canaccord Genuity Group raised their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Stephens restated an “overweight” rating and set a $65.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $60.86.

Vericel Trading Down 0.3%

VCEL opened at $41.73 on Monday. Vericel has a 1-year low of $37.39 and a 1-year high of $63.00. The company has a market capitalization of $2.09 billion, a PE ratio of 695.62 and a beta of 1.31. The firm’s 50 day simple moving average is $43.19 and its two-hundred day simple moving average is $51.27.

Institutional Trading of Vericel

A number of institutional investors and hedge funds have recently bought and sold shares of VCEL. Barclays PLC increased its holdings in Vericel by 145.4% in the 3rd quarter. Barclays PLC now owns 111,527 shares of the biotechnology company’s stock valued at $4,712,000 after acquiring an additional 66,082 shares during the last quarter. Franklin Resources Inc. increased its holdings in Vericel by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 33,543 shares of the biotechnology company’s stock valued at $1,412,000 after acquiring an additional 4,117 shares during the last quarter. Diversified Trust Co bought a new stake in Vericel in the 4th quarter valued at $356,000. Park Avenue Securities LLC bought a new stake in Vericel in the 4th quarter valued at $280,000. Finally, Geneos Wealth Management Inc. increased its holdings in Vericel by 826.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 2,240 shares during the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 24,850 shares of Vericel stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the sale, the chief executive officer now directly owns 260,354 shares in the company, valued at approximately $10,906,229.06. The trade was a 8.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 5.20% of the stock is currently owned by insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.